Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

Novartis Investigative Site, Ghent

Novartis Investigative Site, Berlin

Novartis Investigative Site, Hamburg

Duke Univ Medical Center, Durham

Novartis Investigative Site, Madrid

Medical University of South Carolina MUSC, Charleston

Novartis Investigative Site, Montpellier

Novartis Investigative Site, Chambray-lès-Tours

Novartis Investigative Site, Seville

University Of Cincinnati, Cincinnati

Novartis Investigative Site, Münster

Novartis Investigative Site, Pisa

Novartis Investigative Site, Lille

Northwestern University, Chicago

Wash U School of Medicine, St Louis

The Methodist Hospital, Houston

University of Colorado Hospital - Aurora, Aurora

University of Southern California, Los Angeles

Novartis Investigative Site, Regensburg

Novartis Investigative Site, Villejuif

Henry Ford Hospital, Detroit

Novartis Investigative Site, CABA

Novartis Investigative Site, CABA

Novartis Investigative Site, Caba

Novartis Investigative Site, Prague

Novartis Investigative Site, Budapest

Novartis Investigative Site, Rotterdam

Novartis Investigative Site, L'Hospitalet de Llobregat

Novartis Investigative Site, Barcelona